Navigation Links
New target for cancer therapy may improve treatment for solid tumors
Date:3/3/2008

Targeting and killing the non-malignant cells that surround and support a cancer can stop tumor growth in mice, reports a research team based at the University of Chicago Medical Center in the March 1, 2008, issue of the journal Cancer Research. The discovery offers a new approach to treating cancers that are resistant to standard therapy.

Many solid tumors develop elaborate mechanisms to prevent recognition and elimination by the immune system. Due to their genetic instability they often discard the tumor antigen-presenting cell-surface structures that alert the immune system that these cells are harmful. Without these flags, the white blood cells fail to recognize and kill infected or cancerous cells. These tumors then often grow rapidly and resist treatment with chemotherapy or efforts to boost the immune system's response to the tumor.

But the stroma, the layers of cells that surround a tumor, can accumulate tumor antigens and present them on their surface. These genetically stable surrounding cells retain the molecules that present tumor antigens, which makes them a good target for immunotherapy, and they often play an enabling role in tumor growth.

We already knew that targeting the stroma is essential for eradicating established large tumors, because the stroma is like the 'root of the tumor," said study author Hans Schreiber, MD, PhD, professor of pathology at the University of Chicago. However, effects of current treatments that target stroma are usually transient and not cancer-specific."

"Since cancer is a genetic disease," he said, "we wondered whether mutant proteins are released into the surroundings and picked up by the stroma. If so, we can target the root of the cancer in a cancer-specific way to arrest or eradicate a tumor."

They injected T cells, the immune system's warriors, into mice with large established cancers. These T cells, specifically engineered to recognize the tumor antigen, had no direct impact on the cancerous cells but managed to kill stromal cells. This reduced tumor size and stopped the growth of tumors for more than 80 days.

Although targeting the stroma didn't eliminate all cancer cells, it did stop or slow the growth of well-established cancers after a single injection of T cells.

Such growth arrest in patients would be an admirable achievement for many cancers, the authors write, "and could also be used as an adjuvant to other therapies."

Tumor eradication is obviously preferable to tumor arrest, the authors note. "We can't target cancer cells when they have lost their antigen-presenting molecules, said co-author Bin Zhang, PhD, a former postdoctoral fellow in Schreiber's laboratory and now assistant professor at the University of Texas Health Sciences Center, San Antonio. So stroma becomes an ideal alternative target for T cells."

One concern was that other, healthy cells in tissues like the spleen could also pick up the antigens and become a target for T cells, said Zhang. We did not see this," he added. "Only tumor-derived stromal cells appear to pick up and present tumor antigen.

The next step is to test this approach for melanoma, breast and colon cancer, Zhang said. We know that stromal cells often present tumor-antigen in these tumors, but have not yet performed T cell therapy on these mice.

They are also studying this approach for human cancers. Early results suggest that "this approach might be useful for the human situation as well, Zhang said.


'/>"/>

Contact: John Easton
john.easton@uchospitals.edu
773-702-6241
University of Chicago Medical Center
Source:Eurekalert

Related medicine news :

1. New study of targeted therapies for breast cancer -- model for global clinical trials
2. Weill Cornell team identifies potential new drug targets against hormone-dependent breast cancer
3. Researchers find possible target to treat deadly bloodstream infections
4. Most Internet Sex Offenders Target Teens, Not Kids
5. Novel method to reveal drug targets
6. Tumor-killing virus selectively targets diseased brain cells
7. Enzyme structure reveals new drug targets for cancer and other diseases
8. GPS for the Prostate: System Keeps Radiation Therapy on Target
9. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
10. Childrens Hospital scientists identify possible target for prevention and treatment of pneumonia
11. Campaign Targets Noise-Induced Hearing Loss in Kids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: